Dr. Reddy's Laboratories Ltd. reported strong earnings in the first quarter of fiscal 2024, buoyed by an impressive run in the US amid continued gains from generic (g) Revlimid (lenalidomide).
The company’s senior management, though, underscored that the US performance had “several growth engines” not just lenalidomide. New product launches...








